KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma.
Frost N, Kollmeier J, Vollbrecht C, Grah C, Matthes B, Pultermann D, von Laffert M, Lüders H, Olive E, Raspe M, Mairinger T, Ochsenreither S, Blum T, Hummel M, Suttorp N, Witzenrath M, Grohé C.
Frost N, et al. Among authors: matthes b.
Transl Lung Cancer Res. 2021 Feb;10(2):737-752. doi: 10.21037/tlcr-20-958.
Transl Lung Cancer Res. 2021.
PMID: 33718018
Free PMC article.